Literature DB >> 15571246

Dihydroorotate dehydrogenase mRNA and protein expression analysis in normal and drug-resistant cells.

M Löffler1, A Klein, M Hayek-Ouassini, W Knecht, L Konrad.   

Abstract

To follow the expression of the fourth enzyme of pyrimidine de novo synthesis dihydroorotate dehydrogenase (DHODH) in cells and tissues, we studied the DHODH mRNA expression by means of RT-PCR in rat tissues. Rabbit polyclonal anti-DHODH immunoglobulins were applied for immunochemical quantification of the enzyme protein by Western blotting. In mouse B-lymphocytes, which were adapted to tolerate up to a 50-fold concentration of the DHODH inhibitor leflunomide, a 20 fold protein overexpression was measured. Southern blotting indicated DHODH gene amplification.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571246     DOI: 10.1081/NCN-200027547

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  8 in total

1.  Effect of teriflunomide on QuantiFERON-TB Gold results.

Authors:  Alessandra Bua; Melania Ruggeri; Stefania Zanetti; Paola Molicotti
Journal:  Med Microbiol Immunol       Date:  2016-10-04       Impact factor: 3.402

2.  The Beneficial Clinical Effects of Teriflunomide in Experimental Autoimmune Myasthenia Gravis and the Investigation of the Possible Immunological Mechanisms.

Authors:  Emel Koseoglu; Neslihan Sungur; Sabahattin Muhtaroglu; Gokmen Zararsiz; Ahmet Eken
Journal:  Cell Mol Neurobiol       Date:  2022-10-11       Impact factor: 4.231

3.  A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.

Authors:  Robert J Fox; Heinz Wiendl; Christian Wolf; Nicola De Stefano; Johann Sellner; Viktoriia Gryb; Konrad Rejdak; Plamen Stoyanov Bozhinov; Nataliya Tomakh; Iryna Skrypchenko; Andreas R Muehler
Journal:  Ann Clin Transl Neurol       Date:  2022-06-14       Impact factor: 5.430

Review 4.  Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.

Authors:  María José Zarzuelo Romero; Cristina Pérez Ramírez; María Isabel Carrasco Campos; Almudena Sánchez Martín; Miguel Ángel Calleja Hernández; María Carmen Ramírez Tortosa; Alberto Jiménez Morales
Journal:  J Pers Med       Date:  2021-04-23

5.  Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.

Authors:  Amit Bar-Or; Heinz Wiendl; Barry Miller; Myriam Benamor; Philippe Truffinet; Meg Church; Francoise Menguy-Vacheron
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-02-12

6.  Monitoring of Peripheral Blood Leukocytes and Plasma Samples: A Pilot Study to Examine Treatment Response to Leflunomide in Rheumatoid Arthritis.

Authors:  João F S Rodrigues; Liziane C M da Silva; Leia Cardoso-Sousa; Douglas Carvalho Caixeta; Debora D Lückemeyer; Alisson S Henrique; Jaqueline P Pontes; Lycia M G da Silva; Juliana S S Macedo; Pedro S Carvalho Júnior; Cristiane Silva E Silva; Mahiba M R S Martins; Valério Monteiro-Neto; Marcos A G Grisotto; Anita M R Fernandes; Juliano Ferreira; João B Calixto; Robinson Sabino-Silva; Elizabeth S Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-29

Review 7.  Teriflunomide and its mechanism of action in multiple sclerosis.

Authors:  Amit Bar-Or; Andrew Pachner; Francoise Menguy-Vacheron; Johanne Kaplan; Heinz Wiendl
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 8.  Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.

Authors:  Marc Pawlitzki; Uwe K Zettl; Tobias Ruck; Leoni Rolfes; Hans-Peter Hartung; Sven G Meuth
Journal:  EBioMedicine       Date:  2020-06-11       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.